November 2024

7
Nov
Thu, 11/07/2024 - 00:00
WEBINAR

Application of Indirect Treatment Comparisons

A Science & Innovation Webinar, presented by Abbvie.

The intent of evidence-based health care decision making is to compare all applicable and available treatment options. When direct comparisons from randomized controlled trials are not available, indirect treatment comparisons, including network meta-analyses, may offer valuable insights. In addition, mixed treatment comparisons, a type of network meta-analysis, combine both direct and indirect evidence for specific comparisons, providing a broader view than traditional network meta analysis.

Thursday, Nov. 7, 2024 | 12–1pm ET

November 2024

6
Nov
Wed, 11/06/2024 - 00:00
WEBINAR

A Preventive Treatment Option for Adults with Migraine

A Science & Innovation Webinar, presented by Abbvie.

Migraine is a complex, chronic disease that results in significant patient and economic burden. It is important to appropriately manage a person with migraine who experiences greater than 4 attacks a month (or severe disability from at least two attacks a month) and may benefit from preventive therapy. One of the main goals of preventive therapy is to improve function and reduce disability. Utilizing a stratified care approach to preventive migraine treatment is key to accomplish this goal. During this webinar, a migraine expert will discuss the complexity of migraine disease and the burden of the disease as it relates to function, and the treatment landscape, with a focus on a preventive treatment option for adults with migraine.

Wednesday, Nov. 6, 2024 | 12–1pm ET

November 2024

4
Nov
Mon, 11/04/2024 - 00:00
WEBINAR

A Novel, Once Daily Oral Tablet Being Investigated as the First Treatment for Hyperphagia in Prader-Willi Syndrome (PWS)

A Pre-Approval Information Exchange (PIE) Webinar, presented by Soleno Therapeutics.

Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of a novel therapy to treat Hyperphagia in Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia, neurocognitive and behavioral difficulties. The company is currently pursuing regulatory approval in the United States for its lead investigational candidate, DCCR (diazoxide choline) extended-release tablets.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Monday, November 4, 2024 | 2–3pm ET

October 2024

29-06
Oct
2024
FEATURED
OTHER EVENT

AMCP Award Nominations Due

The AMCP Awards recognize managed care professionals who are making influential strides in the industry.

Nominations close Dec. 6, 2024

Due December 6, 2024